Good News zu VPHM - 500 Beiträge pro Seite

[durt]

Viropharma-Kursverlauf am heutigen
Tage ist doch eine Erwähnung wert!
Anhängig noch eine Viropharma-Information.



Viele Grüsse
durt







ViroPharma Incorporated NASDAQ:VPHM
Industry: Biotechnology&Drugs

Delayed as of 08/2/2000 16:08 EST
At A Glance
Last Sale 18 3/4
Change 1 1/4
% Change 7.14%
Volume 138,100


8 Wireless Stocks Salomon Smith Barney | Get the WhisperNumber
Today`s High 19 3/8 52 Week High 111 5/8
Today`s Low 17 3/8 52 Week Low 10 1/2
Bid 16 1/2 EPS -2.28
Ask 23 1/2 P/E Ratio -8.24
Dividend Per Share 0.00 Market Capitalization 284.70
Open 17 3/8 Shares Outstanding Mil 15.18
Previous Close 17 1/2 Ticks +==-+-=+-=-+----
Last Trade Size 500 Exchange NASDAQ


PR Newswire, 07/27/2000 08:07
ViroPharma Incorporated Reports Second Quarter Financial Results


EXTON, Pa., July 27 /PRNewswire/ -- ViroPharma Incorporated (NASDAQ:VPHM) reported today financial results for the second quarter ended June 30, 2000.





For the quarter ended June 30, 2000, ViroPharma reported a net loss of $5.4 million compared to a net loss of $6.1 million for the same period in 1999. Net loss for the quarter ended June 30, 2000 was adjusted to reflect preferred stock dividends to arrive at net loss allocable to common stockholders. Net loss per share allocable to common stockholders for the quarter ended June 30, 2000 was $0.37 per share, basic and diluted. Without giving effect to the preferred stock dividends, or the beneficial conversion feature recorded in 1999, net loss per share for the quarter ended June 30, 2000 was $0.36 per share, basic and diluted, compared to $0.53 per share, basic and diluted, for the same period in 1999. In the quarter ended June 30, 2000, the company earned license fee revenue of $.25 million in connection with the hepatitis C collaboration with American Home Products Corporation, through its Wyeth-Ayerst Laboratories division. The Company did not earn any revenue in the quarter ended June 30, 1999. Research and development expenses for the second quarter of 2000 were $4.3 million compared to $5.2 million for the same period in 1999. In the second quarter of 2000, the company was preparing to initiate two pivotal trials with pleconaril, the company`s most advanced drug candidate, for the treatment of viral respiratory infection, conducting safety studies with VP50406 for the treatment of hepatitis C and conducting additional preclinical studies with VP14637 for the treatment of RSV pneumonia. In the second quarter of 1999, the company was conducting two clinical trials with pleconaril and advancing both the hepatitis C and RSV pneumonia programs. The decrease in expenses in the second quarter of 2000 was primarily due to the fact that clinical studies for pleconaril were ongoing in the second quarter of 1999, and no such studies were conducted in the same period of 2000. General and administrative expenses for the second quarter of 2000 were $2.1 million compared to $1.2 million for the same period in 1999. The increase is due to employee related expenses and business development activities. As of June 30, 2000 the company had approximately $226 million in cash, cash equivalents and short-term investments.





For the six-month period ended June 30, 2000, ViroPharma reported a net loss of $12.2 million compared to a net loss of $11.8 million for the same period in 1999. Net loss for the six-month period ended June 30, 2000 was adjusted to reflect preferred stock dividends to arrive at net loss allocable to common stockholders. Net loss per share allocable to common stockholders for the six-month period ended June 30, 2000 was $0.83 per share, basic and diluted. Without giving effect to the preferred stock dividends, or the beneficial conversion feature recorded in 1999, net loss per share for the six-month ended June 30, 2000 was $0.80 per share, basic and diluted, compared to $1.02 per share, basic and diluted, for the same period in 1999. In the six-month period ended June 30, 2000, the company earned license fee and milestone revenue of $1.5 million in connection with the hepatitis C collaboration with Wyeth-Ayerst Laboratories. The Company did not earn any revenue in the six-month period ended June 30, 1999. Research and development expenses for the six-month period ended June 30, 2000 were $10.8 million compared to $10.1 million for the same period in 1999. The increase in expenses in the six-month period ended June 30, 2000 was due primarily to the completion of three phase 3 clinical trials of pleconaril, the initiation of safety studies with VP50406 for the treatment of hepatitis C and the advancement of the company`s drug candidate for the treatment of RSV pneumonia. General and administrative expenses were $4.2 million in the six- months ended June 30, 2000 compared to $2.4 million for the same period of 1999. The increase is due to employee related expenses, pre-marketing expenses related to pleconaril and business development activities.





ViroPharma Incorporated is committed to the commercialization, development and discovery of antiviral pharmaceuticals. The Company is focused on drug development and discovery activities in viral diseases including viral respiratory infection (a severe form of the common cold), RSV pneumonia and hepatitis C.


/CONTACT: Vincent J. Milano, Vice President, CFO and Treasurer, or Kori Beer, Director, Corporate Communications, of ViroPharma Incorporated, 610-458-7300/


/Web site: http://www.viropharma.com /

Companies or Securities discussed in this article: Symbol Name
NASDAQ:VPHM ViroPharma Incorporated

[steph312]

Könnt ihr mir sagen, wann der von allen so hochgejubelte Durchbruch des Kurses einsetzen wird? Und haltet ihr die alten Kurse wirklich für realistisch? Außerdem : Denkt ihr das der Kurs von heute auf Morgen explodieren wird (wenn das Medikament nicht durch die klinischen Tests fällt)?

Mit Dank im Voraus

gez.
Stephan Albrecht

[durt]

Hallo Stephan,
Das wird Dir kaum jemand sagen können.
Wenn Du Viropharma-Aktien erwirbst,
verfolge den Kursverlauf sehr intensiv.
Setz einen Dir vernünftig erscheinenden
Stoppkurs und sei Dir des grossen Risikos
bewusst.
Hohes Gewinnpotenzial lockt.
Viel Glück
durt